P09.33 Feasibility and survival benefit of hypofractionated radiotherapy with concurrent temozolomide and bevacizumab in elderly patients with glioblastoma

Abstract

BACKGROUND: Hypofractionated radiotherapy (HPRT) was often used for treatment of elderly patients with glioblastoma. This therapy was well tolerated, however, the prognosis was still dismal. Although dose escalation of HPRT (45Gy/15fr) might be effective, incidence of radiation injury could be increasing. In 2014, Bevacizumab (BEV) was approved for newly diagnosed and recurrent glioblastoma in Japan. It has been reported that BEV is effective for cerebral edema and radiation injury as well as suppreression of tumor growth Object. We investigated whether dose escalated HPRT with concurrent temozolomide and bevacizumab would be well tolerant and effective for patients with elderly patients with glioblastoma METHODS: We analyzed 11 elderly (Age >75) patients with newly diagnosed glioblastoma who received the therapy at our hospital from 2014-2016 with HPRT (45Gy/15fr) delivered with concurrent daily TMZ (75mg/m2). Median preoperative KPS was 90 (60-100). All patients who had GBM progression with TMZ were used of BEV for salvage therapy. RESULTS: All patients completed HPRT with concurrent daily TMZ. All patients received BEV for salvage therapy. With a median follow-up of 15.5 months, 4 (36 %) patients were deceased. The median OS was not reached, while the median PFS was 4 months. Median KPS after 6 months after initial therapy was 70 (50-100). CONCLUSION: Dose escalated HPRT with concurrent temozolomide and bevacizumab was well tolerated and effective for elderly patients with glioblastoma.